Skip to main content

American Bio Medica Corp. (ABMC)

OTCMKTS: ABMC · Delayed Price · USD
0.0375 -0.0025 (-6.25%)
Sep 17, 2021 3:47 PM EDT - Market closed
Market Cap1.64M
Revenue (ttm)2.76M
Net Income (ttm)-1.25M
Shares Out43.80M
EPS (ttm)-0.03
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume45,210
Open0.0387
Previous Close0.0400
Day's Range0.0373 - 0.0387
52-Week Range0.0300 - 0.2900
Beta-2.06
Analystsn/a
Price Targetn/a
Est. Earnings Daten/a

About ABMC

American Bio Medica Corporation develops, manufactures, and sells lateral flow immunoassay tests primarily for the immediate detection of drugs in urine and oral fluids. Its drugs detection products in urine include Rapid Drug Screen, a rapid drug test, which detects the presence or absence of 2 to 10 drugs; RDS InCup, a drug-testing cup that detects the presence or absence of 1 to 12 drugs; Rapid TOX, a drug test in a cassette platform, which detects the presence or absence of 1 to 10 drugs; and Rapid TOX Cup II, a drug testing cup that detect...

IndustryHealth Care Equipment & Supplies
IPO DateDec 24, 1997
Employees39
Stock ExchangeOTCMKTS
Ticker SymbolABMC
Full Company Profile

Financial Performance

In 2020, ABMC's revenue was $4.15 million, an increase of 13.46% compared to the previous year's $3.66 million. Losses were -$796,000, 16.9% more than in 2019.

Financial Statements

News

ABMC Reports Second Quarter 2021 Results

KINDERHOOK, NY / ACCESSWIRE / August 18, 2021 / American Bio Medica Corporation (OTCQB:ABMC) today announced financial results for the three and six months ended June 30, 2021. Chief Executive Officer M...

1 month ago - Accesswire

ABMC Reports First Quarter 2021 Results

KINDERHOOK, NY / ACCESSWIRE / May 20, 2021 / American Bio Medica Corporation (OTCQB:ABMC) today announced financial results for the three months ended March 31, 2021. Chief Executive Officer Melissa A.

3 months ago - Accesswire